LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Arcus Biosciences Inc

Slēgts

SektorsVeselības aprūpe

9.99 3.85

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.58

Max

10.09

Galvenie mērījumi

By Trading Economics

Ienākumi

-18M

-112M

Pārdošana

2M

28M

EPS

-1.14

Peļņas marža

-400

Darbinieki

627

EBITDA

-34M

-122M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+189.51% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

11M

976M

Iepriekšējā atvēršanas cena

6.14

Iepriekšējā slēgšanas cena

9.99

Ziņu noskaņojums

By Acuity

100%

0%

369 / 380 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

Arcus Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 6. jūn. 14:31 UTC

Peļņas

New York State Retirement Fund Posts 5.84% Annual Investment Return

2025. g. 6. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 6. jūn. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 6. jūn. 20:33 UTC

Peļņas

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 19:36 UTC

Tirgus saruna

Oil Futures Post Solid Weekly Gains -- Market Talk

2025. g. 6. jūn. 19:28 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

2025. g. 6. jūn. 18:46 UTC

Tirgus saruna

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

2025. g. 6. jūn. 18:02 UTC

Tirgus saruna

U.S. Oil Rig Count Continues to Decline -- Market Talk

2025. g. 6. jūn. 16:35 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 16:34 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 16:21 UTC

Tirgus saruna

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 6. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 6. jūn. 16:07 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 6. jūn. 16:07 UTC

Tirgus saruna

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

2025. g. 6. jūn. 15:53 UTC

Tirgus saruna

Mexican Inflation Seen Rising in May -- Market Talk

2025. g. 6. jūn. 15:36 UTC

Tirgus saruna

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

2025. g. 6. jūn. 15:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 6. jūn. 15:33 UTC

Tirgus saruna

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

2025. g. 6. jūn. 15:16 UTC

Tirgus saruna

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

2025. g. 6. jūn. 15:05 UTC

Tirgus saruna

Silver at its Highest In Nearly 15 Years -- Market Talk

2025. g. 6. jūn. 14:35 UTC

Tirgus saruna

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

2025. g. 6. jūn. 14:15 UTC

Tirgus saruna

Oil Rises on U.S.-China Talks Optimism -- Market Talk

2025. g. 6. jūn. 14:12 UTC

Peļņas

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

2025. g. 6. jūn. 14:09 UTC

Peļņas

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Arcus Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

189.51% augšup

Prognoze 12 mēnešiem

Vidējais 27.88 USD  189.51%

Augstākais 46 USD

Zemākais 12 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Arcus Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

9

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

8.01 / 8.75Atbalsts un pretestība

Īstermiņā

Neutral Evidence

Vidējā termiņā

Neutral Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

369 / 380 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.